Teva Pharmaceutical Industries
TEVA
#675
Rank
$36.16 B
Marketcap
$31.05
Share price
-2.20%
Change (1 day)
102.15%
Change (1 year)

P/E ratio for Teva Pharmaceutical Industries (TEVA)

P/E ratio as of March 2026 (TTM): 25.1

According to Teva Pharmaceutical Industries's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.0605. At the end of 2024 the company had a P/E ratio of -15.2.

P/E ratio history for Teva Pharmaceutical Industries from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-15.2-25.75%
2023-20.5375.85%
2022-4.30-120.41%
202121.1
2019-10.760.27%
2018-6.65470.31%
2017-1.17-100.23%
20165011393.06%
201533.5127.09%
201414.8-38.26%
201323.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Novartis
NVS
21.7-13.39%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
19.6-21.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
21.6-13.96%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
15.7-37.21%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
36.3 45.03%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
14.5-42.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Dr. Reddy's Laboratories
RDY
18.4-26.43%๐Ÿ‡ฎ๐Ÿ‡ณ India

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.